NGP 555, a γ-secretase modulator, lowers the amyloid biomarker, Aβ42 in cerebrospinal fluid while preventing Alzheimer's disease cognitive decline in rodents

Maria Z. Kounnas, Courtney Lane-Donovan, Dan W. Nowakowski, Joachim Herz, William T. Comer

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction Alzheimer's disease (AD) is defined by the progressive accumulation of amyloid plaques and neurofibrillary tangles in the brain which precedes cognitive decline by years. Methods Using amyloid biomarkers, chemical modeling, mouse behavioral models, and drug development techniques, we investigate the properties of NGP 555, a clinical-stage γ-secretase modulator. Results NGP 555 shifts amyloid peptide production to the smaller, nonaggregating forms of amyloid. Our preclinical studies show beneficial effects on amyloid biomarkers, pathology, and cognition. NGP 555 has successfully completed chemistry, pharmacology, toxicity, metabolism, and safety studies. Discussion Abundant data support Aβ42 as a target for prophylactic or early-stage intervention therapies in AD. The γ-secretase modulator, NGP 555 is being actively developed in human clinical trials for the prevention of Alzheimer's disease with the overall aim to achieve an appropriate balance of potency/efficacy on reducing the toxic forms of amyloid versus safety.

Original languageEnglish (US)
Pages (from-to)65-73
Number of pages9
JournalAlzheimer's and Dementia: Translational Research and Clinical Interventions
Volume3
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Amyloid Precursor Protein Secretases
Amyloid
Cerebrospinal Fluid
Rodentia
Alzheimer Disease
Biomarkers
Safety
Neurofibrillary Tangles
Poisons
Amyloid Plaques
Cognition
Cognitive Dysfunction
Clinical Trials
Pharmacology
Pathology
Peptides
Brain
Pharmaceutical Preparations

Keywords

  • Alzheimer's
  • Amyloid
  • Biomarkers
  • Cerebrospinal fluid
  • Cognition
  • Dementia
  • Gamma-secretase
  • Modulator
  • Pathology
  • Prevention

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

NGP 555, a γ-secretase modulator, lowers the amyloid biomarker, Aβ42 in cerebrospinal fluid while preventing Alzheimer's disease cognitive decline in rodents. / Kounnas, Maria Z.; Lane-Donovan, Courtney; Nowakowski, Dan W.; Herz, Joachim; Comer, William T.

In: Alzheimer's and Dementia: Translational Research and Clinical Interventions, Vol. 3, No. 1, 01.01.2017, p. 65-73.

Research output: Contribution to journalArticle

@article{9cb5e6d205724979841dfd5eef8bd78b,
title = "NGP 555, a γ-secretase modulator, lowers the amyloid biomarker, Aβ42 in cerebrospinal fluid while preventing Alzheimer's disease cognitive decline in rodents",
abstract = "Introduction Alzheimer's disease (AD) is defined by the progressive accumulation of amyloid plaques and neurofibrillary tangles in the brain which precedes cognitive decline by years. Methods Using amyloid biomarkers, chemical modeling, mouse behavioral models, and drug development techniques, we investigate the properties of NGP 555, a clinical-stage γ-secretase modulator. Results NGP 555 shifts amyloid peptide production to the smaller, nonaggregating forms of amyloid. Our preclinical studies show beneficial effects on amyloid biomarkers, pathology, and cognition. NGP 555 has successfully completed chemistry, pharmacology, toxicity, metabolism, and safety studies. Discussion Abundant data support Aβ42 as a target for prophylactic or early-stage intervention therapies in AD. The γ-secretase modulator, NGP 555 is being actively developed in human clinical trials for the prevention of Alzheimer's disease with the overall aim to achieve an appropriate balance of potency/efficacy on reducing the toxic forms of amyloid versus safety.",
keywords = "Alzheimer's, Amyloid, Biomarkers, Cerebrospinal fluid, Cognition, Dementia, Gamma-secretase, Modulator, Pathology, Prevention",
author = "Kounnas, {Maria Z.} and Courtney Lane-Donovan and Nowakowski, {Dan W.} and Joachim Herz and Comer, {William T.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.trci.2016.09.003",
language = "English (US)",
volume = "3",
pages = "65--73",
journal = "Alzheimer's and Dementia: Translational Research and Clinical Interventions",
issn = "2352-8737",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - NGP 555, a γ-secretase modulator, lowers the amyloid biomarker, Aβ42 in cerebrospinal fluid while preventing Alzheimer's disease cognitive decline in rodents

AU - Kounnas, Maria Z.

AU - Lane-Donovan, Courtney

AU - Nowakowski, Dan W.

AU - Herz, Joachim

AU - Comer, William T.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Introduction Alzheimer's disease (AD) is defined by the progressive accumulation of amyloid plaques and neurofibrillary tangles in the brain which precedes cognitive decline by years. Methods Using amyloid biomarkers, chemical modeling, mouse behavioral models, and drug development techniques, we investigate the properties of NGP 555, a clinical-stage γ-secretase modulator. Results NGP 555 shifts amyloid peptide production to the smaller, nonaggregating forms of amyloid. Our preclinical studies show beneficial effects on amyloid biomarkers, pathology, and cognition. NGP 555 has successfully completed chemistry, pharmacology, toxicity, metabolism, and safety studies. Discussion Abundant data support Aβ42 as a target for prophylactic or early-stage intervention therapies in AD. The γ-secretase modulator, NGP 555 is being actively developed in human clinical trials for the prevention of Alzheimer's disease with the overall aim to achieve an appropriate balance of potency/efficacy on reducing the toxic forms of amyloid versus safety.

AB - Introduction Alzheimer's disease (AD) is defined by the progressive accumulation of amyloid plaques and neurofibrillary tangles in the brain which precedes cognitive decline by years. Methods Using amyloid biomarkers, chemical modeling, mouse behavioral models, and drug development techniques, we investigate the properties of NGP 555, a clinical-stage γ-secretase modulator. Results NGP 555 shifts amyloid peptide production to the smaller, nonaggregating forms of amyloid. Our preclinical studies show beneficial effects on amyloid biomarkers, pathology, and cognition. NGP 555 has successfully completed chemistry, pharmacology, toxicity, metabolism, and safety studies. Discussion Abundant data support Aβ42 as a target for prophylactic or early-stage intervention therapies in AD. The γ-secretase modulator, NGP 555 is being actively developed in human clinical trials for the prevention of Alzheimer's disease with the overall aim to achieve an appropriate balance of potency/efficacy on reducing the toxic forms of amyloid versus safety.

KW - Alzheimer's

KW - Amyloid

KW - Biomarkers

KW - Cerebrospinal fluid

KW - Cognition

KW - Dementia

KW - Gamma-secretase

KW - Modulator

KW - Pathology

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=85012306899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012306899&partnerID=8YFLogxK

U2 - 10.1016/j.trci.2016.09.003

DO - 10.1016/j.trci.2016.09.003

M3 - Article

VL - 3

SP - 65

EP - 73

JO - Alzheimer's and Dementia: Translational Research and Clinical Interventions

JF - Alzheimer's and Dementia: Translational Research and Clinical Interventions

SN - 2352-8737

IS - 1

ER -